Selskabets formål er import, marketing, emballering, salg, distribution, forskning, udvikling og produktion af medicinalprodukter og andre former for medicinalrelaterede produkter, herunder også medicinal uddannelse, samt al virksomhed, som efter bestyrelsens skøn er beslægtet hermed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 186.8 mio. | 5.1 mio. | 103.4 mio. | 65.1 mio. | 10 | |
CVR: 30899032
Companies in the same industry and area
CVR 26308836
CVR 82591419
CVR 36405449
CVR 25784723
CVR 36669381
Compared to 158 companies in Agenturhandel med specialiseret varesortiment, bortset fra køretøjer
Comparison is based on industry median values
Gilead Sciences Denmark ApS demonstrates a stable financial health with a notable increase in revenue, rising from 109.9 million DKK in 2023 to 186.8 million DKK in 2025. Profitability has fluctuated slightly, with profits peaking at 5.9 million DKK in 2024 before declining to 5.1 million DKK in 2025, indicating a potential concern in maintaining margins. The company's equity has shown a steady upward trend, reaching 65.1 million DKK in 2025, which strengthens its financial position within the specialized goods trading industry. Overall, while the revenue trajectory is positive, the profit margins warrant attention to ensure sustainable growth.
AI-generated summary
companydata.dk